Global
# |
Name |
Price to Book Ratio (P/B) |
Reported Date | Stock Price |
Change |
Price (30 days) | Country |
---|---|---|---|---|---|---|---|
1 |
191.62 |
Jan. 14, 2025 | USD 5.19 | 2.25% |
|
China |
|
2 |
104.48 |
Jan. 14, 2025 | USD 9.47 | -3.37% |
|
United States |
|
3 |
97.62 |
Jan. 14, 2025 | USD 209.72 | 3.60% |
|
South Korea |
|
4 |
93.47 |
Jan. 14, 2025 | USD 0.09 | 2.54% |
|
United Kingdom |
|
5 |
83.50 |
Jan. 14, 2025 | USD 1.05 | 3.96% |
|
United States |
|
6 |
75.79 |
Jan. 14, 2025 | USD 0.18 | 4.90% |
|
Sweden |
|
7 |
65.06 |
Jan. 14, 2025 | USD 16.65 | -8.42% |
|
United States |
|
8 |
51.66 |
Jan. 14, 2025 | USD 64.52 | 1.38% |
|
South Korea |
|
9 |
51.03 |
Jan. 14, 2025 | USD 15.47 | 4.25% |
|
Australia |
|
10 |
48.22 |
Jan. 14, 2025 | USD 1.94 | -0.97% |
|
France |
|
11 |
47.04 |
Jan. 14, 2025 | USD 53.94 | -1.73% |
|
United States |
|
12 |
44.46 |
Jan. 14, 2025 | USD 2.08 | 3.06% |
|
India |
|
13 |
40.35 |
Jan. 14, 2025 | USD 32.97 | -0.61% |
|
Sweden |
|
14 |
39.80 |
Jan. 14, 2025 | USD 175.55 | -0.67% |
|
United States |
|
15 |
38.83 |
Jan. 14, 2025 | USD 12.69 | -0.78% |
|
United States |
|
16 |
37.74 |
Jan. 14, 2025 | USD 20.34 | -1.25% |
|
Poland |
|
17 |
36.47 |
Jan. 14, 2025 | USD 4.34 | 1.19% |
|
Ireland |
|
18 |
31.18 |
Jan. 14, 2025 | USD 11.12 | 2.21% |
|
United States |
|
19 |
30.90 |
Jan. 14, 2025 | USD 84.60 | -5.23% |
|
United States |
|
20 |
29.71 |
Jan. 14, 2025 | USD 7.92 | 0.31% |
|
||
21 |
29.64 |
Jan. 14, 2025 | USD 4.25 | 1.59% |
|
France |
|
22 |
28.80 |
Jan. 14, 2025 | USD 0.83 | 3.77% |
|
China |
|
23 |
28.72 |
Jan. 14, 2025 | USD 95.84 | 0.08% |
|
Denmark |
|
24 |
27.29 |
Jan. 14, 2025 | USD 53.83 | -0.57% |
|
United States |
|
25 |
27.14 |
Jan. 14, 2025 | USD 75.63 | -3.02% |
|
South Korea |
|
26 |
26.82 |
Jan. 14, 2025 | USD 29.74 | 7.48% |
|
United States |
|
27 |
26.73 |
Jan. 14, 2025 | USD 165.76 | -2.09% |
|
United States |
|
28 |
25.34 |
Jan. 14, 2025 | USD 80.54 | 1.08% |
|
||
29 |
25.05 |
Jan. 14, 2025 | USD 41.53 | -2.51% |
|
United States |
|
30 |
24.25 |
Jan. 14, 2025 | USD 102.56 | -0.77% |
|
United States |
|
31 |
24.24 |
Jan. 14, 2025 | USD 81.26 | -0.29% |
|
India |
|
32 |
23.25 |
Jan. 14, 2025 | USD 267.10 | -1.14% |
|
United States |
|
33 |
22.89 |
Jan. 14, 2025 | USD 17.07 | -8.18% |
|
United States |
|
34 |
21.79 |
Jan. 14, 2025 | USD 0.16 | -0.68% |
|
United Kingdom |
|
35 |
21.76 |
Jan. 14, 2025 | USD 16.32 | -1.03% |
|
United States |
|
36 |
21.00 |
Jan. 14, 2025 | USD 91.43 | -1.85% |
|
Denmark |
|
37 |
20.04 |
Jan. 14, 2025 | USD 8.76 | -1.71% |
|
Finland |
|
38 |
18.96 |
Jan. 14, 2025 | USD 12.59 | -1.02% |
|
United States |
|
39 |
18.81 |
Jan. 14, 2025 | USD 1.33 | 6.17% |
|
Australia |
|
40 |
18.28 |
Jan. 14, 2025 | USD 9.21 | -0.22% |
|
United States |
|
41 |
18.00 |
Jan. 14, 2025 | USD 1.60 | 0.81% |
|
India |
|
42 |
17.65 |
Jan. 14, 2025 | USD 0.15 | 4.16% |
|
Japan |
|
43 |
17.25 |
Jan. 14, 2025 | USD 21.07 | 1.40% |
|
South Korea |
|
44 |
17.10 |
Jan. 14, 2025 | USD 82.00 | -1.10% |
|
United States |
|
45 |
16.81 |
Jan. 14, 2025 | USD 0.17 | -2.50% |
|
Norway |
|
46 |
16.37 |
Jan. 14, 2025 | USD 4.78 | -2.00% |
|
Japan |
|
47 |
15.49 |
Jan. 14, 2025 | USD 126.89 | -0.24% |
|
United States |
|
48 |
15.38 |
Jan. 14, 2025 | USD 26.89 | 2.81% |
|
India |
|
49 |
15.29 |
Jan. 14, 2025 | USD 17.87 | 3.09% |
|
Sweden |
|
50 |
15.18 |
Jan. 14, 2025 | USD 37.58 | 0.68% |
|
India |
The Biotechnology company with the highest Price to Book Ratio (P/B) is Ascentage Pharma Group International (HKSE: 6855.HK) at 191.62.
The Biotechnology company with the lowest Price to Book Ratio (P/B) is 4basebio PLC (LSE: 4BB.L) at -377.29.
The top 10 Biotechnology companies the Global by Price to Book Ratio (P/B) are Ascentage Pharma Group International, Evolus, Inc., ALTEOGEN Inc., Allergy Therapeutics plc, Nuwellis, Inc., LifeClean International AB (publ), Summit Therapeutics Inc., Peptron, Inc., Telix Pharmaceuticals Limited and NFL Biosciences SA.
The bottom 10 Biotechnology companies by Price to Book Ratio (P/B) are 4basebio PLC, Alnylam Pharmaceuticals, Inc., Insmed Incorporated, Champions Oncology, Inc., Nanobiotix S.A., Nanologica AB (publ), Basilea Pharmaceutica AG, Fennec Pharmaceuticals Inc., UroGen Pharma Ltd. and Cytokinetics, Incorporated.